Literature DB >> 25309151

Cinacalcet administration by gastrostomy tube in a child receiving peritoneal dialysis.

Kristen R Nichols1, Chad A Knoderer2, Bethanne Johnston3, Amy C Wilson3.   

Abstract

A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercalcemia while receiving calcitriol, without achieving a serum parathyroid hormone concentration within the goal range. Cinacalcet 15 mg (1.2 mg/kg), crushed and administered via gastrostomy tube, was added to the patient's therapy. This therapy was effective in achieving targeted laboratory parameters in our patient despite instructions in the prescribing information that cinacalcet should always be taken whole.

Entities:  

Keywords:  chronic kidney disease; cinacalcet; hypercalcemia; secondary hyperparathyroidism

Year:  2014        PMID: 25309151      PMCID: PMC4187525          DOI: 10.5863/1551-6776-19.3.202

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  10 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

Review 2.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

3.  Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.

Authors:  Larry A Greenbaum; Ryszard Grenda; Ping Qiu; Irene Restaino; Amy Wojtak; Ana Paredes; Nadine Benador; Joel Z Melnick; Laura A Williams; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

Review 4.  Are new vitamin D analogues in renal bone disease superior to calcitriol?

Authors:  Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

5.  Middle-term use of Cinacalcet in paediatric dialysis patients.

Authors:  Caroline Platt; Carol Inward; Mary McGraw; Jan Dudley; Jane Tizard; Christine Burren; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2009-10-17       Impact factor: 3.714

6.  Cinacalcet is efficacious in pediatric dialysis patients.

Authors:  Douglas M Silverstein; Kanwal K Kher; Asha Moudgil; Mona Khurana; Jennifer Wilcox; Kathleen Moylan
Journal:  Pediatr Nephrol       Date:  2008-02-21       Impact factor: 3.714

7.  Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.

Authors:  Jutta Muscheites; Marianne Wigger; Erdmute Drueckler; Dagmar-Christiane Fischer; Guenther Kundt; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2008-05-27       Impact factor: 3.714

8.  Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Authors:  Larry A Greenbaum; Nadine Benador; Stuart L Goldstein; Ana Paredes; Joel Z Melnick; Susan Mattingly; Michael Amdahl; Laura A Williams; Isidro B Salusky
Journal:  Am J Kidney Dis       Date:  2007-06       Impact factor: 8.860

9.  An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.

Authors:  Desmond Padhi; Craig B Langman; Sahar Fathallah-Shaykh; Bradley A Warady; Isidro B Salusky; Edward Lee; Christine Wang; Edward Posvar
Journal:  Pediatr Nephrol       Date:  2012-05-26       Impact factor: 3.714

10.  Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.

Authors:  Yueh-Ting Lee; Hwee-Yeong Ng; Chien-Chun Kuo; Te-Chuan Chen; Chien-Shing Wu; Terry Ting-Yu Chiu; Wen-Chin Lee; Chien-Te Lee
Journal:  Nutrients       Date:  2013-04-19       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.